Structural Characterization of a Neutralizing MAb H16.001, a Potent Candidate for a Common Potency Assay for Various HPV16 VLPs

Overview

Journal NPJ Vaccines

Date 2020 Oct 12

PMID 33042588

Citations 4

Authors

Weijin Huang

Maozhou He

Tingting Ning

Jianhui Nie

Feng Zhang

Qingbing Zheng

Rui Zhang

Ying Xu

Ying Gu

Shaowei Li

Youchun Wang

Affiliations

Soon will be listed here.

Abstract

With more human papillomavirus (HPV) virus-like particle (VLP) vaccines to hit the market in future, a monoclonal antibody (mAb) with preferably comparable reactivity against vaccines from different expression systems and bioprocesses is urgently needed for the potency characterization. Among all mAbs against HPV16 collected, rabbit mAb H16.001 is potently neutralizing with the highest affinity, recognizes an immune-dominant epitope, and can comparably react with HPV16 vaccines from various sources. Cryo-electron microscopic (cryo-EM) structure demonstrated that 360 H16.001 Fabs could bind to HPV16 capsid in preferable binding manner without steric hindrance between neighboring Fabs, potentially supporting its identification for VLP structural integrity and utility in monitoring VLP structural probity. This structural analysis indicated that mAb H16.001 afforded unbiased potency characterization for various HPV16 vaccines and was potential for use in vaccine regulation practice. This study also showed a model process for selecting suitable mAbs for potency assays of other vaccines.

Citing Articles

B-cell epitope discovery: The first protein flexibility-based algorithm-Zika virus conserved epitope demonstration.

Biner D, Grosch J, Ortoleva P PLoS One. 2023; 18(3):e0262321.

PMID: 36920995 PMC: 10016673. DOI: 10.1371/journal.pone.0262321.

Critical Residues Involved in the Coassembly of L1 and L2 Capsid Proteins of Human Papillomavirus 16.

Chen J, Wang D, Wang Z, Wu K, Wei S, Chi X J Virol. 2023; 97(3):e0181922.

PMID: 36815785 PMC: 10062154. DOI: 10.1128/jvi.01819-22.

Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies.

Sanyal G NPJ Vaccines. 2022; 7(1):50.

PMID: 35513416 PMC: 9072649. DOI: 10.1038/s41541-022-00470-4.

Cryo EM Analysis Reveals Inherent Flexibility of Authentic Murine Papillomavirus Capsids.

Hartmann S, Goetschius D, Hu J, Graff J, Bator C, Christensen N Viruses. 2021; 13(10).

PMID: 34696452 PMC: 8537154. DOI: 10.3390/v13102023.

References

Zhang Z, Zhang J, Xia N, Zhao Q . Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2017; 13(10):2280-2291. PMC: 5647960. DOI: 10.1080/21645515.2017.1346755. View

Nie J, Huang W, Wu X, Wang Y . Optimization and validation of a high throughput method for detecting neutralizing antibodies against human papillomavirus (HPV) based on pseudovirons. J Med Virol. 2014; 86(9):1542-55. DOI: 10.1002/jmv.23995. View

Li N, Franceschi S, Howell-Jones R, Snijders P, Clifford G . Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2010; 128(4):927-35. DOI: 10.1002/ijc.25396. View

Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L . Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993; 67(12):6929-36. PMC: 238150. DOI: 10.1128/JVI.67.12.6929-6936.1993. View

Qiao Y, Wu T, Li R, Hu Y, Wei L, Li C . Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2019; 112(2):145-153. PMC: 7019098. DOI: 10.1093/jnci/djz074. View

Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S . Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin. 2011; 7(12):1343-58. PMC: 3338932. DOI: 10.4161/hv.7.12.18281. View

Zheng S, Palovcak E, Armache J, Verba K, Cheng Y, Agard D . MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat Methods. 2017; 14(4):331-332. PMC: 5494038. DOI: 10.1038/nmeth.4193. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Draper E, Bissett S, Howell-Jones R, Waight P, Soldan K, Jit M . A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One. 2013; 8(5):e61825. PMC: 3641072. DOI: 10.1371/journal.pone.0061825. View

10.

Shank-Retzlaff M, Wang F, Morley T, Anderson C, Hamm M, Brown M . Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin. 2006; 1(5):191-7. DOI: 10.4161/hv.1.5.2126. View

11.

Scheres S, Chen S . Prevention of overfitting in cryo-EM structure determination. Nat Methods. 2012; 9(9):853-4. PMC: 4912033. DOI: 10.1038/nmeth.2115. View

12.

Li Z, Wang D, Gu Y, Song S, He M, Shi J . Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus. mBio. 2017; 8(5). PMC: 5615192. DOI: 10.1128/mBio.00787-17. View

13.

Lee H, Brendle S, Bywaters S, Guan J, Ashley R, Yoder J . A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. J Virol. 2014; 89(2):1428-38. PMC: 4300654. DOI: 10.1128/JVI.02898-14. View

14.

Ning T, Wolfe A, Nie J, Huang W, Chen X, Wang Y . Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization. J Infect Dis. 2017; 216(7):867-876. DOI: 10.1093/infdis/jix274. View

15.

Ilca S, Kotecha A, Sun X, Poranen M, Stuart D, Huiskonen J . Localized reconstruction of subunits from electron cryomicroscopy images of macromolecular complexes. Nat Commun. 2015; 6:8843. PMC: 4667630. DOI: 10.1038/ncomms9843. View

16.

Pastrana D, Buck C, Pang Y, Thompson C, Castle P, FitzGerald P . Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology. 2004; 321(2):205-16. DOI: 10.1016/j.virol.2003.12.027. View

17.

Kucukelbir A, Sigworth F, Tagare H . Quantifying the local resolution of cryo-EM density maps. Nat Methods. 2013; 11(1):63-5. PMC: 3903095. DOI: 10.1038/nmeth.2727. View

18.

MATUMOTO M . A note on some points of calculation method of LD50 by Reed and Muench. Jpn J Exp Med. 1949; 20(2):175-9. View

19.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

20.

Grant T, Rohou A, Grigorieff N . TEM, user-friendly software for single-particle image processing. Elife. 2018; 7. PMC: 5854467. DOI: 10.7554/eLife.35383. View